TY - JOUR
T1 - Emerging treatments in advanced urothelial cancer
AU - Alhalabi, Omar
AU - Campbell, Matthew
AU - Shah, Amishi
AU - Siefker-Radtke, Arlene
AU - Gao, Jianjun
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Purpose of reviewUrothelial carcinoma is one of the 10 most common forms of cancer in the world with more than half a million cases diagnosed yearly. The past few years have witnessed a revolution in understanding the biology of urothelial carcinoma and the development of promising therapies. In this review, we summarize the emerging therapeutic approaches in the management of advanced urothelial carcinoma.Recent findingsSince 2016, the Food and Drug Administration (FDA) has approved five checkpoint inhibitors (CPIs), a fibroblast growth factor receptor (FGFR) inhibitor, and an antibody drug conjugate (ADC) for the treatment of advanced urothelial carcinoma. Additionally, the FDA has granted several breakthrough designations for other therapeutic strategies including other ADCs.SummaryCPIs, anti-FGFR agents and ADCs are significant advancements that offer new treatment options to patients with advanced urothelial carcinoma. However, there remains a need to understand mechanisms of resistance, identify biomarkers to choose potential responders, and learn the best strategy to sequence these agents in regards to lines of therapy.
AB - Purpose of reviewUrothelial carcinoma is one of the 10 most common forms of cancer in the world with more than half a million cases diagnosed yearly. The past few years have witnessed a revolution in understanding the biology of urothelial carcinoma and the development of promising therapies. In this review, we summarize the emerging therapeutic approaches in the management of advanced urothelial carcinoma.Recent findingsSince 2016, the Food and Drug Administration (FDA) has approved five checkpoint inhibitors (CPIs), a fibroblast growth factor receptor (FGFR) inhibitor, and an antibody drug conjugate (ADC) for the treatment of advanced urothelial carcinoma. Additionally, the FDA has granted several breakthrough designations for other therapeutic strategies including other ADCs.SummaryCPIs, anti-FGFR agents and ADCs are significant advancements that offer new treatment options to patients with advanced urothelial carcinoma. However, there remains a need to understand mechanisms of resistance, identify biomarkers to choose potential responders, and learn the best strategy to sequence these agents in regards to lines of therapy.
KW - FGFR
KW - antibody-drug conjugates
KW - immune checkpoint inhibitors
KW - targeted therapy
KW - urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85083041321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083041321&partnerID=8YFLogxK
U2 - 10.1097/CCO.0000000000000618
DO - 10.1097/CCO.0000000000000618
M3 - Review article
C2 - 32209822
AN - SCOPUS:85083041321
SN - 1040-8746
VL - 32
SP - 232
EP - 239
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 3
ER -